These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9169660)

  • 1. The significance of light chain-restricted bone marrow plasma cells after peripheral blood stem cell transplantation for multiple myeloma.
    Maia DM; Kell DL; Goates JJ; Warnke RA
    Am J Clin Pathol; 1997 Jun; 107(6):643-52. PubMed ID: 9169660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma.
    Harousseau JL; Attal M; Divine M; Milpied N; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M
    Bone Marrow Transplant; 1995 Jun; 15(6):963-9. PubMed ID: 7581098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the efficiency of free light chain assay in monitoring patients with multiple myeloma before and after autologous stem cell transplantation along with serum protein electrophoresis and serum protein immunofixation.
    Dogaru M; Lazăr V; Coriu D
    Roum Arch Microbiol Immunol; 2011; 70(1):15-22. PubMed ID: 21717807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of bone marrow sections, smears and immunohistological staining for immunoglobulin light chains in the diagnosis of benign and malignant plasma cell proliferations.
    Thiry A; Delvenne P; Fontaine MA; Boniver J
    Histopathology; 1993 May; 22(5):423-8. PubMed ID: 7688339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Clonal Plasma Cell Contamination of Peripheral Blood Stem Cell Autografts on Progression and Survival in Multiple Myeloma Patients After Autologous Peripheral Blood Stem Cell Transplantation in Long-term Observation.
    Waszczuk-Gajda A; Feliksbrot-Bratosiewicz M; Król M; Snarski E; Drozd-Sokołowska J; Biecek P; Król M; Lewandowski Z; Peradzyńska J; Jędrzejczak WW; Dwilewicz-Trojaczek J
    Transplant Proc; 2018 Sep; 50(7):2202-2211. PubMed ID: 30177137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.
    Powles R; Raje N; Horton C; Mehta J; Singhal S; Hickish T; Viner C; Milan S; Treleaven J; Cunningham D
    Leuk Lymphoma; 1996 May; 21(5-6):421-7. PubMed ID: 9172806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.
    Raje N; Powles R; Horton C; Millar B; Shepherd V; Middleton G; Kulkarni S; Eisen T; Mehta J; Singhal S; Treleaven J
    Br J Cancer; 1997; 75(11):1684-9. PubMed ID: 9184187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of CD34+ cell selected and unselected autologous peripheral blood stem cell transplantation for multiple myeloma: a case controlled analysis.
    Gandhi M; Jestice H; Scott M; Bloxham D; Bass G; Craig J; Marcus R
    Bone Marrow Transplant; 1999 Aug; 24(4):369-75. PubMed ID: 10467325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the S-phase fraction of light-chain-restricted cytoplasmic immunoglobulin (cIg) positive plasma cells in patients with newly diagnosed multiple myeloma enrolled on Eastern Cooperative Oncology Group treatment trial E9486.
    Trendle MC; Leong T; Kyle RA; Katzmann JA; Oken MM; Kay NE; Van Ness BG; Greipp PR
    Am J Hematol; 1999 Aug; 61(4):232-7. PubMed ID: 10440908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of marrow hematogones following autologous stem cell transplant in adult patients with plasma cell myeloma or diffuse large B-cell lymphoma and correlation with outcome.
    Santiago V; Lazaryan A; McClune B; McKenna RW; Courville EL
    Leuk Lymphoma; 2018 Apr; 59(4):958-966. PubMed ID: 28728454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotyping studies of clonotypic B lymphocytes from patients with multiple myeloma by flow cytometry.
    Conway EJ; Wen J; Feng Y; Mo A; Huang WT; Keever-Taylor CA; Hari P; Vesole DH; Chang CC
    Arch Pathol Lab Med; 2009 Oct; 133(10):1594-9. PubMed ID: 19792049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma.
    Duncan N; Hewetson M; Powles R; Raje N; Mehta J
    Bone Marrow Transplant; 1996 Dec; 18(6):1175-8. PubMed ID: 8971391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faster engraftment but no reduction in infectious complications after peripheral blood stem cell transplantation compared to autologous bone marrow transplantation.
    Larsson K; Björkstrand B; Ljungman P
    Support Care Cancer; 1998 Jul; 6(4):378-83. PubMed ID: 9695206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of molecular marker-positive cells after autologous peripheral-blood stem-cell transplantation for non-Hodgkin's lymphoma.
    Hardingham JE; Kotasek D; Sage RE; Gooley LT; Mi JX; Dobrovic A; Norman JE; Bolton AE; Dale BM
    J Clin Oncol; 1995 May; 13(5):1073-9. PubMed ID: 7738613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis.
    Kourelis TV; Kumar SK; Gertz MA; Lacy MQ; Buadi FK; Hayman SR; Zeldenrust S; Leung N; Kyle RA; Russell S; Dingli D; Lust JA; Lin Y; Kapoor P; Rajkumar SV; McCurdy A; Dispenzieri A
    J Clin Oncol; 2013 Dec; 31(34):4319-24. PubMed ID: 24145344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.
    Dinner S; Witteles W; Witteles R; Lam A; Arai S; Lafayette R; George TI; Schrier SL; Liedtke M
    Br J Haematol; 2013 May; 161(3):367-72. PubMed ID: 23432783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of myeloma cell contamination of bone marrow and peripheral blood stem cell harvests.
    Henry JM; Sykes PJ; Brisco MJ; To LB; Juttner CA; Morley AA
    Br J Haematol; 1996 Mar; 92(3):614-9. PubMed ID: 8616025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.